Pscilly

DEA proposes higher 2027 quotas for psilocybin and other psychedelics

By · Published · Updated

The Drug Enforcement Administration has proposed raising 2027 production quotas for several psychedelics, including psilocybin and psilocyn, according to a draft Federal Register notice filed Monday. The proposal covers production for medical, scientific, research and industrial purposes; it does not change the substances’ Schedule I status. The agency proposes allowing 60,000 grams of psilocybin in 2027, up from 50,000 grams in 2026. The proposed quota for psilocyn, a related chemical, would rise from 80,000 to 93,600 grams. DEA also seeks to increase the quota for MDMA from 12,000 to 33,296 grams and for ibogaine from 210 to 12,002 grams. The notice says the higher quotas for MDMA and ibogaine are intended to support manufacturing tied to increased research and clinical trials, including studies of potential treatments for PTSD and depression. Marijuana production quotas for Schedule I research would remain at 2026 levels under this proposal. DEA said it is registering manufacturers and distributors for marijuana and cannabinoids moved to Schedule III, and assessing data to estimate production needs for those substances. It plans a separate notice on proposed Schedule III quotas once they are determined. A separate proceeding is considering whether to move non-medical marijuana to Schedule III. DEA said the quota notice will be formally published Wednesday, after which the public will have 30 days to comment. For mushroom readers, the proposed psilocybin increase is a notable change in the federal research and production framework, not a broader change to the substance’s legal status.

Published
November 9, 2026
Source
marijuanamoment.net